Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready to use, which can save time and reduce costs. It targets two proteins, CD19 and CD20, to lower the chance of relapse and uses gene editing to make it safer. The trial has three parts: first to find a safe dose, then to confirm it, and finally to test how well it works in patients with diffuse large B-cell lymphoma (DLBCL). Patients will get one infusion after chemotherapy to prepare their body. The main goal is to check safety and see how many patients have a complete response by Week 13. About 160 patients will take part, and researchers will follow them for up to 15 years.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Rozpoznany nawrót lub oporność na leczenie chłoniaka B-komórkowego lub białaczki limfocytowej
- •Poprzednio leczony co najmniej dwoma schematami terapii
- •Zdolność do wykonywania codziennych czynności
- •Prawidłowe funkcjonowanie serca, wątroby i nerek
- •Zgodność HLA z komórkami dawcy
- •Brak aktywnych niekontrolowanych infekcji
✗ Disqualifies
- •Poprzednia terapia CAR-T w ciągu ostatnich 3 miesięcy
- •Przeszczep szpiku lub transplantacja narządu w przeszłości
- •Poważna alergia na leki używane w badaniu
- •Historia choroby przeszczepowo-przeciwko-gospodarzowej
- •Aktywna infekcja wirusowa, bakteryjna lub grzybicza
- •Aktywna choroba autoimmunologiczna wymagająca leczenia
- •Zaburzenia neurologiczne w ciągu ostatnich 6 miesięcy
- •Poważna choroba serca w ciągu ostatnich 6 miesięcy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 28, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (13)
University of Chicago
Chicago, United States
Northwestern University
Evanston, United States
Brown University Health
Providence, United States
Sarah Cannon Research Institute
Nashville, United States
MD Anderson Cancer Center
Houston, United States
Universitätsklinikum Ulm
Ulm, Germany
Universitätsklinikum Erlangen
Erlangen, Germany
Klinikum der Universität München
Munich, Germany
Universitätsklinikum Marburg
Marburg, Germany
Uniklinikum Erlangen
Essen, Germany
Universitätsklinikum Dresden
Dresden, Germany
Charité Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Trial contact
Antje Warth, Dr.
Katja Jersemann, Dr.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/29/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.